Compare
Fennec Pharmaceuticals Inc. vs Editas Medicine, Inc. vs Voyager Therapeutics, Inc. vs Sangamo Therapeutics, Inc
| Latest fiscal year | Fennec Pharmaceuticals Inc. FENC | Editas Medicine, Inc. EDIT | Voyager Therapeutics, Inc. VYGR | Sangamo Therapeutics, Inc SGMOQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.64M | $40.52M | $40.37M | $39.55M |
| Revenue growth (YoY) | -6.1% | +25.4% | -49.5% | -31.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -14.1% | -394.9% | -326.6% | -306.5% |
| Net margin | -21.8% | -395.0% | -296.5% | -310.8% |
| Net income | -$9.74M | -$160.06M | -$119.72M | -$122.93M |
| EPS (Diluted) | -$0.34 | -$1.80 | -$2.04 | -$0.44 |
| Operating cash flow | -$12.47M | -$165.24M | -$132.47M | -$97.21M |
| Free cash flow | n/a | -$165.85M | -$135.06M | -$97.31M |
| Cash & equivalents | $36.79M | $146.65M | $65.30M | $20.95M |
| Total assets | $70.55M | $186.53M | $252.28M | $59.74M |
| Total liabilities | $35.08M | $159.25M | $56.20M | $74.01M |
| Shareholders' equity | $35.47M | $27.29M | $196.08M | -$14.27M |
| Return on year-end equity | -27.5% | -586.6% | -61.1% | n/a |
| Shares outstanding | 34.16M | 97.87M | 59.05M | 350.69M |
Revenue, most recent five fiscal years
| Fiscal year | Fennec Pharmaceuticals Inc. | Editas Medicine, Inc. | Voyager Therapeutics, Inc. | Sangamo Therapeutics, Inc |
|---|---|---|---|---|
| Latest | $44.64M Ended 2025-12-31 | $40.52M Ended 2025-12-31 | $40.37M Ended 2025-12-31 | $39.55M Ended 2025-12-31 |
| 1 year earlier | $47.54M Ended 2024-12-31 | $32.31M Ended 2024-12-31 | $80.00M Ended 2024-12-31 | $57.80M Ended 2024-12-31 |
| 2 years earlier | $21.25M Ended 2023-12-31 | $78.12M Ended 2023-12-31 | $250.01M Ended 2023-12-31 | $176.23M Ended 2023-12-31 |
| 3 years earlier | $1.53M Ended 2022-12-31 | $19.71M Ended 2022-12-31 | $40.91M Ended 2022-12-31 | $111.30M Ended 2022-12-31 |
| 4 years earlier | n/a | $25.54M Ended 2021-12-31 | $37.41M Ended 2021-12-31 | $110.70M Ended 2021-12-31 |